Generating hepatocytes

Patent metadata

Field	Value
Publication number	US-9512406-B2
Application number	US-201414578377-A
Country	US
Kind code	B2
Filing date	Dec 20, 2014
Priority date	Dec 20, 2013
Publication date	Dec 6, 2016
Grant date	Dec 6, 2016

Abstract

Compositions and methods are described herein for inducing reprogramming of non-pluripotent cells across lineage and differentiation boundaries to generate endodermal progenitor cells and hepatocytes. Compositions and methods for expansion of endodermal progenitor cells without loss of phenotype are also described herein.

First claim

What is claimed:

1. A method comprising administering to a subject one or more immature hepatocytes generated as follows:
(a) incubating one or more cells with a first composition comprising an epidermal growth factor (EGF), a basic fibroblast growth factor (bFGF), an activator of WNT signaling, a nuclear receptor liver receptor homolog 1 agonist, a histone deacetylase (HDAC) inhibitor, a histone demethylase LSD1 inhibitor, and a DNA methyltransferase (DNMT) inhibitor to generate induced multipotent cells;
(b) incubating the induced multipotent cells with a second composition comprising an activator of WNT signaling, a nuclear receptor liver receptor homolog 1 agonist, a histone deacetylase (HDAC) inhibitor, a histone demethylase LSD1 inhibitor, a DNA methyltransferase (DNMT) inhibitor, Activin A, or any combination thereof to generate one or more endodermal progenitor cells;
(c) optionally incubating the one or more endodermal progenitor cells in a third composition comprising epidermal growth factor (EGF), basic fibroblast growth factor (bFGF), and a TGF-beta inhibitor for a time and in a sufficient amount of the third composition to generate an endodermal progenitor cell population; and
(d) incubating the one or more endodermal progenitor cells or the endodermal progenitor cell population in a fourth composition comprising basic fibroblast growth factor (bFGF), a TGF-beta inhibitor, bone morphogenetic protein 4 (BMP4), and dexamethasone for a time and in a sufficient amount of the composition to generate one or more immature hepatocytes.

2. The method of claim 1 , wherein the one or more cells of step (a) is a heterogeneous or homogeneous mixture of cells.

3. The method of claim 1 , wherein the one or more cells of step (a) is incubated with the composition for a time and with an amount of the composition sufficient to induce the one or more cells to express SOX17, FOXA2, HNF4α, or any combination thereof.

4. The method of claim 1 , wherein the one or more cells of step (a) is incubated with the first composition for about 2 days to about 30 days, or from 3 days to about 25 days, or from 4 days to about 20 days, or from 5 days to about 9 days.

5. The method of claim 1 , wherein the first composition does not induce a cell to express OCT4, Nanog, or a combination thereof.

6. The method of claim 1 , where the induced multipotent cells express SOX17, FOXA2, HNF4α, or any combination thereof.

7. The method of claim 1 wherein the induced multipotent cells are incubated with the second composition for a time and/or with an amount of the composition sufficient to induce generation of the one or more endodermal progenitor cells.

8. The method of claim 1 furthering comprising administering one or more cells from the endodermal progenitor cell population to a subject.

9. The method of claim 1 further comprising incubating the one or more endodermal progenitor cells, the endodermal progenitor cell population, the one more immature hepatocytes, or a combination thereof in a composition comprising a TGF-beta inhibitor, hepatocyte growth factor, a Notch inhibitor, oncostatin M (OSM), or any combination thereof for a time and in a sufficient amount of the composition to generate one or more mature hepatocytes.

10. The method of claim 9 , further comprising administering one or more mature hepatocytes to a subject.

11. The method of claim 1 , wherein the subject suffers from a liver condition or disease.

12. The method of claim 11 , wherein the liver condition or disease is chronic liver failure, tyrosinemia type I, cirrhosis, Alagille syndrome, hepatitis, alcoholic liver disease, liver cancer, hepatic steatosis, liver fibrosis, liver cysts, primary schlerosing cholangitis, hemochromatosis, Wilson's disease, alcoholic hepatitis, enlarged liver, transthyretin-related hereditary amyloidosis, Gilbert's syndrome, jaundice, liver hemangioma, non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, primary sclerosing cholangitis, or a combination thereof.

Assignees

• The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone
• The J David Gladstone Inst A Testamentary Trust Established Under The Will Of J David Gladstone
• Univ California

Inventors

• Zhu Saiyong
• Ding Sheng
• Willenbring Holger
• Rezvani Milad
• Harbell Jack

Classifications

• A61K38/1808

  Epidermal growth factor [EGF] urogastrone · CPC title

• A61K38/1825

  Fibroblast growth factor [FGF] · CPC title

• C12N2501/72

  Transferases [EC 2.] · CPC title

• C12N2501/42

  Notch; Delta; Jagged; Serrate · CPC title

• A61K38/1875

  Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor · CPC title